+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
524414 NORRIS

Norris Medicines Share Price

 

 

Norris Medicines live price: ₹13.51. It opened at ₹14 vs previous close ₹13; intraday high/low: ₹14/₹14. The 50 & 200 DMA stand at ₹13.80/₹14.82.

Norris Medicines Performance

  • Today's Low
  • ₹14
  • Today's High
  • ₹14
  • 52 Week Low
  • ₹12
  • 52 Week High
  • ₹19
  • Open Price₹14
  • Previous Close₹13
  • Volume452
  • 50 DMA₹13.80
  • 100 DMA₹14.09
  • 200 DMA₹14.82

Norris Medicines Chart

Investment Returns

  • Over 1 Month -4.79%
  • Over 3 Month + 4.16%
  • Over 6 Month -19.34%
  • Over 1 Year -28.29%

Smart Investing Starts Here Start SIP with Norris Medicines for Steady Growth!

Invest Now

Norris Medicines Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -48.2
  • PEG Ratio
  • -0.6
  • Market Cap Cr
  • 14
  • P/B Ratio
  • -0.9
  • Average True Range
  • 0.94
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.03
  • RSI
  • 48.51
  • MFI
  • 66.89

Norris Medicines Financials

Norris Medicines Technicals

EMA & SMA

Current Price
₹13.51
+ 0.16 (1.2%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹13.70
  • 50 Day
  • ₹13.80
  • 100 Day
  • ₹14.10
  • 200 Day
  • ₹14.80

Resistance and Support

13.71 Pivot Speed
  • R3 14.53
  • R2 14.31
  • R1 13.93
  • S1 13.33
  • S2 13.11
  • S3 12.73

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Norris Medicines has an operating revenue of Rs. 8.13 Cr. on a trailing 12-month basis. An annual revenue growth of 39% is outstanding, Pre-tax margin of -3% needs improvement, NULL It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 38 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Norris Medicines Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-30 Audited Results
2026-02-14 Quarterly Results
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results
2025-05-28 Audited Results

Norris Medicines Shareholding Pattern

34.01%
0.01%
0.06%
20.77%
45.15%

Norris Medicines FAQs

Norris Medicines share price is ₹13 As on 27 June, 2026 | 17:21

The Market Cap of Norris Medicines is ₹13.5 Cr As on 27 June, 2026 | 17:21

The P/E ratio of Norris Medicines is -48.2 As on 27 June, 2026 | 17:21

The PB ratio of Norris Medicines is -0.9 As on 27 June, 2026 | 17:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23